Cox proportional hazards models for mortality of CLL patients according to VTE, patient-specific factors, and CLL-specific factors
| . | HR, crude (95% CI) . | HR, multivariable (95% CI)* . |
|---|---|---|
| Sex | ||
| Female | Reference | Reference |
| Male | 1.23 (1.06-1.43) | 1.59 (1.36-1.86) |
| Age, y | ||
| ≤60 | Reference | Reference |
| >60 to ≤70 | 3.51 (2.33-5.28) | 3.44 (2.28-5.19) |
| >70 to ≤80 | 7.56 (5.09-11.24) | 6.90 (4.63-10.28) |
| >80 | 16.72 (11.25-24.83) | 12.99 (8.68-19.45) |
| WHO-PF | ||
| 0-1 | Reference | Reference |
| >1 | 6.34 (5.17-7.76) | 3.14 (2.53-3.89) |
| Second primary cancer | ||
| No | Reference | Reference |
| Yes | 6.94 (3.45-13.95) | 5.85 (2.90-11.79) |
| VTE after CLL | ||
| No | Reference | Reference |
| Yes | 2.20 (1.43-3.37) | 2.13 (1.39-3.27) |
| IgHV mutational status | ||
| Mutated | Reference | Reference |
| Unmutated | 1.52 (1.26-1.84) | 1.47 (1.22-1.78) |
| Not assessed | 2.44 (2.06-2.90) | 1.60 (1.33-1.90) |
| β2-microglobulin, mg/L | ||
| <4 | Reference | Reference |
| ≥4 | 3.38 (2.76-4.13) | 1.86 (1.51-2.29) |
| Not assessed | 1.64 (1.39-1.93) | 1.19 (1.00-1.41) |
| . | HR, crude (95% CI) . | HR, multivariable (95% CI)* . |
|---|---|---|
| Sex | ||
| Female | Reference | Reference |
| Male | 1.23 (1.06-1.43) | 1.59 (1.36-1.86) |
| Age, y | ||
| ≤60 | Reference | Reference |
| >60 to ≤70 | 3.51 (2.33-5.28) | 3.44 (2.28-5.19) |
| >70 to ≤80 | 7.56 (5.09-11.24) | 6.90 (4.63-10.28) |
| >80 | 16.72 (11.25-24.83) | 12.99 (8.68-19.45) |
| WHO-PF | ||
| 0-1 | Reference | Reference |
| >1 | 6.34 (5.17-7.76) | 3.14 (2.53-3.89) |
| Second primary cancer | ||
| No | Reference | Reference |
| Yes | 6.94 (3.45-13.95) | 5.85 (2.90-11.79) |
| VTE after CLL | ||
| No | Reference | Reference |
| Yes | 2.20 (1.43-3.37) | 2.13 (1.39-3.27) |
| IgHV mutational status | ||
| Mutated | Reference | Reference |
| Unmutated | 1.52 (1.26-1.84) | 1.47 (1.22-1.78) |
| Not assessed | 2.44 (2.06-2.90) | 1.60 (1.33-1.90) |
| β2-microglobulin, mg/L | ||
| <4 | Reference | Reference |
| ≥4 | 3.38 (2.76-4.13) | 1.86 (1.51-2.29) |
| Not assessed | 1.64 (1.39-1.93) | 1.19 (1.00-1.41) |
Adjusted for all other variables in the table (VTE and second primary cancer following CLL diagnosis as time-varying exposures and age as age + age2).